Old and new biomarkers of heart failure

European Journal of Heart Failure

Volumn 11, Issue 4, 2009, Pages 331-335

  Emdin, Michele ^a   Vittorini, Simona ^a   Passino, Claudio ^a,b   Clerico, Aldo ^a,b  

^a CNR   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

Cardiovascular biomarkers; Evidence based laboratory medicine; Heart failure; Natriuretic peptides; Risk factor; Troponins

Indexed keywords

ADIPONECTIN; ADRENOMEDULLIN; ARGIPRESSIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CATECHOLAMINE; CHROMOGRANIN A; CHROMOGRANIN B; CYTOKINE; ENDOTHELIN; FAS ANTIGEN; FATTY ACID BINDING PROTEIN; GALECTIN 3; HYDROCORTISONE; INTERCELLULAR ADHESION MOLECULE 1; ISOPROSTANE; LEPTIN; MALONALDEHYDE; MATRIX METALLOPROTEINASE; MYELOPEROXIDASE; OSTEOPONTIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PENTRAXIN 3; PROCOLLAGEN; RESISTIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TROPONIN; URIC ACID;

COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; FEASIBILITY STUDY; GENETIC ANALYSIS; HEART FAILURE; HUMAN; LABORATORY TEST; NOTE; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPRODUCIBILITY; SENSITIVITY ANALYSIS; STANDARDIZATION; URIC ACID BLOOD LEVEL;

BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TROPONIN;

EID: 66249144415     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp035     Document Type: Note

References (45)

1. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation 2000;102(20 Suppl. 4):IV14-IV23.
2. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:2148-2159.
3. Vasan S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:2335-2362.
4. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. Clin Chem 2004;50: 33-50.
5. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004;164: 1978-1984.
6. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 2005;330:625-627.
7. Clerico A, Fontana M, Zyw L, Passino C, Emdin M. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the n-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 2007;53:813-822.
8. Lee DS, Vasan RS. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 2005;20:201-210.
9. Macabasco-O'Connell A, Miller PS. Biomarkers for heart failure. Prog Cardiovasc Nurs 2006;21:215-218.
10. De Virginy DR. Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart faille: a clinical review. Heart Fail Rev 2006;11:333-334.
11. Lainscak M, von Haehling S, Springer J, Anker SD. Biomarkers for chronic heart failure. Heart Fail Monit 2007;5:77-82.
12. Vittorini S, Clerico A. Cardiovascular biomarkers: increasing impact of laboratory medicine in cardiology practice. Clin Chem Lab Med 2008;46:748-763.
13. Marshall DA, O'Brien BJ. Economic evaluation of diagnostic tests. In: Price PC, Christensen RH eds. Evidence-based Laboratory Medicine - From Principles to Outcomes. Washington, DC: AACC Press; 2003. p159-186.
14. Hense HW. Observations, predictions and decisions - assessing cardiovascular risk assessment. Int J Epidemiol 2004;33:235-239.
15. Valenstein PN. Evaluating diagnostic tests with imperfect standards. Am J Clin Pathol 1990;93:252-258.
16. Biesheuvel C, Irwig L, Bossuyt P. Observed differences in diagnostic test accuracy between patient subgroups. Is it real or due to reference standard misclassifi-cations? Clin Chem 2007;53:1725-1729.
17. Emdin M, Passino C, Prontera C, Fontana M, Poletti R, Gabutti A, Mammini C, Giannoni A, Zyw L, Zucchelli G, Clerico A. Comparison of brain natriuretic peptide (BNP) and amino-terminal proBNP for early diagnosis of heart failure. Clin Chem 2007;53:1264-1272.
18. Wang JT. New cardiovascular risk factors exist, but are they clinically useful? Eur Heart J 2008;2:441 -444.
19. Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Int Med J 2008;38:101-113.
20. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, d'Eril GM, Moratti R, Merlini G. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloi-dosis. Circulation 2003;107:2440-2445.
21. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloi-dosis undergoing peripheral blood stem cell transplantation. Blood 2004;104: 1881-1887.
22. Yasutake H, Seino Y, Kashiwagi M, Honma H, Matsuzaki T, Takano T. Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. Int J Cardiol 2005;102:259-268.
23. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G, Fiorentini C, Cipolla CM. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-2754.
24. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civelli M, Martinelli G, Cipolla CM. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005;51:1405-1410.
25. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474-2481.
26. Price CP. Evidence-based laboratory medicine: supporting decision making. Clin Chem 2000;46:1041-1050.
27. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Lévy S, Linde C, Lopez-Sendon JL, Nieminen MS, Piérard L, Remme WJ. Guidelines for the diagnosis, treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-1140.
28. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC Guidelines for the diagnosis treatment of acute, chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). EurJ Heart Fail 2008;10:933-989.
29. Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006;290:H17-H29.
30. Morrow DA, Antman EM. Evaluation of high-sensitivity assays for cardiac troponin. Clin Chem 2009;55:5-8.
31. Wang TJ. Significance of circulating troponins in heart failure: if these walls could talk. Circulation 2007;116:1217-1220.
32. Clerico A, Fortunato A, Prontera C, Ripoli A, Zucchelli GC, Emdin M. Distribution of plasma cardiac troponin-I values in healthy subjects: pathophysiological considerations. Clin Chem Lab Med 2008;46:804- 808.
33. Swaanenburg JCJM, Visser-VanBrummen PJ, DeJongste MJL, Tiebosch ATHM. The content and distribution of troponin I, troponin T, myoglobin, and alpha-hydrobytyric acid dehydrogenase in the human heart. Am J Clin Pathol 2001;115:770-777.
34. Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A, McGuire DK, Wians F, Sabatine MS, Morrow DA, de Lemos JA. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006;113:1958- 1965.
35. Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN, Val-HeFT Investigators. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007;116:1242-1249.
36. Richard P, Villard E, Charron P, Isnard R. The genetic bases of cardiomyopathies. J Am Coll Cardiol 2006;48:A79-A89.
37. Donahue MP, Douglas A, Marchuk DA, Rockman HA. Redefining heart failure. The utility of genomics. J Am Coll Cardiol 2006;48:1289-1298.
38. Rehman SU, Mueller T,JanuzziJLJr. Characteristics ofthenovelinterleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008;52:1458-1465.
39. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, Sagara M, Kubota I. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008;155:75-81.
40. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-1224.
41. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, Ponikowski P, Filippatos GS, Rozentryt P, Drexler H, Anker SD, Wollert KC. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007;50:1054-1060.
42. Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007;13:42-49.
43. Frankel DS, Vasan RS, D'Agostino RB Sr, Benjamin EJ, Levy D, Wang TJ, Meigs JB. Resistin, Adiponectin, and Risk of Heart Failure: The Framingham Offspring Study. J Am Coll Cardiol. Expedited Publication 22 December 2008.
44. Jaffe AS. Key issues in the developing synergism between cardiovascular imaging and biomarkers. Clin Chem 2008;54:1432-1442.
45. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL. The human disease network. Proc Natl Acad Sci USA 2007;104:8685-8690.